跳转至内容
Merck
CN
  • miR-203a suppresses cell proliferation by targeting RING-finger protein 6 in colorectal cancer.

miR-203a suppresses cell proliferation by targeting RING-finger protein 6 in colorectal cancer.

Anti-cancer drugs (2020-04-14)
Jiyu Miao, Ni Hou, Wanwan Yang, Qiuyu Jiang, Wanjuan Xue, Xiaofei Wang, Huahua Zhang, Xiaofan Xiong, Lumin Wang, Lingyu Zhao, Chen Huang
摘要

Colorectal cancer (CRC) is one of most common cancers worldwide. Although miR-203a is reported as a tumor suppressor involved in cell progression in some cancers, the role of miR-203a in CRC is still controversial and the underling mechanism of miR-203a in CRC remains unclear. Here, we demonstrated that low expression of miR-203a had poorer survival in CRC patients. miR-203a was down-regulated in most human colon cancer cells. Overexpression of miR-203a could inhibit colon cancer cell proliferation and arrest cell cycle in G1 phase. Bioinformatics and dual luciferase reporter assay confirmed that RING-finger protein 6 (RNF6) was a target gene of miR-203a. Silencing RNF6 inhibited cell proliferation and arrest cell cycle in G1 phase. RNF6 overexpression reversed the effects of miR-203a overexpression in colon cancer cells. Taken together, our data indicate that miR-203a inhibits colon cancer cell proliferation by targeting RNF6, offer novel insights into the regulatory network of miR-203a-modulated cell cycle and proliferation, and suggest that miR-203a a potential therapeutic target in CRC treatment.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human RNF6